{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:12:46Z","timestamp":1791202366382,"version":"4.2.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":1749,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.jhep.2008.07.005","type":"journal-article","created":{"date-parts":[[2008,7,18]],"date-time":"2008-07-18T09:11:28Z","timestamp":1216372288000},"page":"625-633","source":"Crossref","is-referenced-by-count":129,"title":["Acute hepatitis C: Current status and remaining challenges"],"prefix":"10.1016","volume":"49","author":[{"given":"Teresa","family":"Santantonio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Wiegand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Tilman Gerlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2008.07.005_bib1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1053\/jhep.2001.22112","article-title":"Acute hepatitis C","volume":"33","author":"Orland","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2008.07.005_bib2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/hep.21902","article-title":"Acute hepatitis C virus infection: a chronic problem","volume":"47","author":"Blackard","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2008.07.005_bib3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1046\/j.1365-2893.2000.00179.x","article-title":"Prevention of hepatitis C in Italy: lessons from surveillance of type-specific acute viral hepatitis. SEIEVA collaborating Group","volume":"7","author":"Mele","year":"2000","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2008.07.005_bib4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1046\/j.1365-2141.2002.03334.x","article-title":"An estimate of the current risk of transmitting blood-borne infections through blood transfusion in Italy","volume":"117","author":"Tosti","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jhep.2008.07.005_bib5","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1136\/gut.50.5.693","article-title":"Infection rate and spontaneous seroreversion of anti-hepatitis C virus during the natural course of hepatitis C virus infection in the general population","volume":"50","author":"Kondili","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2008.07.005_bib6","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJM199908193410802","article-title":"The prevalence of hepatitis C virus infection in the United States, 1988 through 1994","volume":"341","author":"Alter","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2008.07.005_bib7","first-page":"1","article-title":"Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease","volume":"47","year":"1998","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jhep.2008.07.005_bib8","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1016\/S0002-9343(99)00373-3","article-title":"Epidemiology of hepatitis C in the United States","volume":"107","author":"Williams","year":"1999","journal-title":"Am J Med"},{"key":"10.1016\/j.jhep.2008.07.005_bib9","unstructured":"Centers for Disease Control and Prevention. Surveillance for acute viral hepatitis United States, 2005. 56th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2007. p. 1\u201324."},{"key":"10.1016\/j.jhep.2008.07.005_bib10","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1086\/507640","article-title":"Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy","volume":"43","author":"Santantonio","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2008.07.005_bib11","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.cgh.2006.06.026","article-title":"Outcomes and treatment of acute hepatitis C virus infection in a United States population","volume":"4","author":"Corey","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2008.07.005_bib12","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jhep.2007.07.033","article-title":"The changing epidemiology of hepatitis C virus infection in Europe","volume":"48","author":"Esteban","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2008.07.005_bib13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhep.2007.07.031","article-title":"Hospital admission is a relevant source of hepatitis C virus acquisition in Spain","volume":"48","author":"Martinez-Bauer","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2008.07.005_bib14","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s00108-007-1912-z","article-title":"Injuries from needles contaminated with hepatitis C virus: how high is the risk of seroconversion for medical personnel really?","volume":"48","author":"Kubitschke","year":"2007","journal-title":"Der Internist (Berl)"},{"key":"10.1016\/j.jhep.2008.07.005_bib15","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/hep.21043","article-title":"Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study","volume":"43","author":"Wiegand","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2008.07.005_bib16","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1053\/j.gastro.2006.01.034","article-title":"Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response","volume":"130","author":"Kamal","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2008.07.005_bib17","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/hep.21197","article-title":"Duration of peginterferon therapy in acute hepatitis C: a randomized trial","volume":"43","author":"Kamal","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2008.07.005_bib18","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/hep.20119","article-title":"Diagnosis, management, and treatment of hepatitis C","volume":"39","author":"Strader","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2008.07.005_bib19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1053\/j.gastro.2005.11.010","article-title":"American Gastroenterological Association technical review on the management of hepatitis C","volume":"130","author":"Dienstag","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2008.07.005_bib20","unstructured":"World Health Organization. Hepatitis C. World Health Organization 2000 October [cited 2006 Apr 12];1-3."},{"key":"10.1016\/j.jhep.2008.07.005_bib21","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1590-8658(03)00007-0","article-title":"Natural course of acute hepatitis C: a long-term prospective study","volume":"35","author":"Santantonio","year":"2003","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2008.07.005_bib22","unstructured":"Heathcote J, Elewaut A, Fedail S, Gangl A, Hamid S, Shah M, et al. WGO practice guideline: management of acute viral hepatitis. World Gastroenterology Organisation Web site 2003 December [cited 2007 Sep 14]. Available from: URL: http:\/\/www.worldgastroenterology.org\/management-of-acute-viral-hepatitis.html."},{"key":"10.1016\/j.jhep.2008.07.005_bib23","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/j.jhep.2004.10.017","article-title":"Acute hepatitis C: diagnosis and management","volume":"42","author":"Mondelli","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2008.07.005_bib24","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1002\/hep.1840360709","article-title":"Use and interpretation of virological tests for hepatitis C","volume":"36","author":"Pawlotsky","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2008.07.005_bib25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1055\/s-2005-864778","article-title":"Acute hepatitis C: a multifaceted disease","volume":"25","author":"Heller","year":"2005","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2008.07.005_bib26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2893.2005.00651.x","article-title":"Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies","volume":"13","author":"Micallef","year":"2006","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2008.07.005_bib27","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0016-5085(03)00668-1","article-title":"Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance","volume":"125","author":"Gerlach","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2008.07.005_bib28","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1053\/jhep.2003.50019","article-title":"Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load","volume":"37","author":"Hofer","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2008.07.005_bib29","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/jmv.20103","article-title":"High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection","volume":"73","author":"Lehmann","year":"2004","journal-title":"J Med Virol"},{"key":"10.1016\/j.jhep.2008.07.005_bib30","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/hep.20266","article-title":"Pegylated interferon \u03b1 therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics","volume":"39","author":"Kamal","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2008.07.005_bib31","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0140-6736(95)91691-1","article-title":"Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection","volume":"346","author":"Diepolder","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2008.07.005_bib32","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0016-5085(99)70353-7","article-title":"Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C","volume":"117","author":"Gerlach","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2008.07.005_bib33","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1086\/315450","article-title":"Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C","volume":"181","author":"Gruner","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2008.07.005_bib34","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1002\/1521-4141(200009)30:9<2479::AID-IMMU2479>3.0.CO;2-B","article-title":"CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained","volume":"30","author":"Lechner","year":"2000","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jhep.2008.07.005_bib35","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1084\/jem.194.10.1395","article-title":"Determinants of viral clearance and persistence during acute hepatitis C virus infection","volume":"194","author":"Thimme","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.jhep.2008.07.005_bib36","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1126\/science.1088774","article-title":"HCV persistence and immune evasion in the absence of memory T cell help","volume":"302","author":"Grakoui","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.jhep.2008.07.005_bib37","doi-asserted-by":"crossref","first-page":"12252","DOI":"10.1128\/JVI.78.22.12252-12258.2004","article-title":"Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients","volume":"78","author":"Kamal","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2008.07.005_bib38","doi-asserted-by":"crossref","first-page":"e649","DOI":"10.1371\/journal.pone.0000649","article-title":"Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection","volume":"2","author":"Lucas","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jhep.2008.07.005_bib39","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1017\/S0950268806006388","article-title":"Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users","volume":"135","author":"Amin","year":"2007","journal-title":"Epidemiol Infect"},{"issue":"3","key":"10.1016\/j.jhep.2008.07.005_bib40","first-page":"CD000369","article-title":"Interferon for acute hepatitis C (review)","author":"Myers","year":"2002","journal-title":"The Cochrane Library"},{"key":"10.1016\/j.jhep.2008.07.005_bib41","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1007\/BF02088245","article-title":"Interferon as treatment for acute hepatitis C: a meta-analysis","volume":"41","author":"Camm\u00e0","year":"1996","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2008.07.005_bib42","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/hep.510240405","article-title":"Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration","volume":"24","author":"Poynard","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2008.07.005_bib43","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0168-8278(03)00461-6","article-title":"When and how to treat acute hepatitis C?","volume":"39","author":"Licata","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2008.07.005_bib44","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1056\/NEJMoa011232","article-title":"Treatment of acute hepatitis C with interferon alfa-2b","volume":"345","author":"Jaeckel","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2008.07.005_bib45","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.20291","article-title":"Long-term follow-up after successful interferon therapy of acute hepatitis C","volume":"40","author":"Wiegand","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2008.07.005_bib46","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2036.2004.02023.x","article-title":"Treatment of acute hepatitis C with interferon \u03b1-2b: early initiation of treatment is the most effective predictive factor of sustained viral response","volume":"20","author":"Delwaide","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2008.07.005_bib47","doi-asserted-by":"crossref","first-page":"81S","DOI":"10.1007\/BF02087880","article-title":"High-dose interferon-\u03b12b treatment prevents chronicity in acute hepatitis C: a pilot study","volume":"41","author":"Vogel","year":"1996","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2008.07.005_bib48","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/hep.20196","article-title":"Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial","volume":"39","author":"Nomura","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2008.07.005_bib49","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhep.2004.11.021","article-title":"Efficacy of a 24-week course of PEG-interferon \u03b1-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance","volume":"42","author":"Santantonio","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2008.07.005_bib50","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/jac\/dki458","article-title":"Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C","volume":"57","author":"De Rosa","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jhep.2008.07.005_bib51","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1086\/520660","article-title":"Twelve-week treatment of acute hepatitis C virus with pegylated interferon-\u03b1-2b in injection drug users","volume":"45","author":"De Rosa","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2008.07.005_bib52","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1365-2893.2006.00802.x","article-title":"A short course of pegylated interferon-\u03b1 in acute HCV hepatitis","volume":"14","author":"Calleri","year":"2007","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2008.07.005_bib53","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients","volume":"351","author":"Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2008.07.005_bib54","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1001\/jama.292.23.2839","article-title":"Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial","volume":"292","author":"Carrat","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2008.07.005_bib55","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons","volume":"351","author":"Chung","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2008.07.005_bib56","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1097\/01.aids.0000226956.02719.fd","article-title":"Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients","volume":"20","author":"Dominguez","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2008.07.005_bib57","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/01.qai.0000174930.64145.a9","article-title":"Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin","volume":"40","author":"Gilleece","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jhep.2008.07.005_bib58","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/01.aids.0000200541.40633.56","article-title":"Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy","volume":"20","author":"Serpaggi","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2008.07.005_bib59","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/135965350601100817","article-title":"Pegylated interferon-\u03b1 for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals","volume":"11","author":"Vogel","year":"2006","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.jhep.2008.07.005_bib60","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1055\/s-2004-832931","article-title":"Hepatitis C infection associated with renal disease and chronic renal failure","volume":"24","author":"Poordad","year":"2004","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2008.07.005_bib61","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/01.meg.0000252626.73172.f3","article-title":"Interferon-alpha therapy within the first year after acute hepatitis C infection in hemodialysis patients: efficacy and tolerance","volume":"19","author":"Rocha","year":"2007","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2008.07.005_bib62","first-page":"293","article-title":"Treatment of acute hepatitis C virus infection with alpha interferon in patients on hemodialysis","volume":"16","author":"Al-Harbi","year":"2005","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"10.1016\/j.jhep.2008.07.005_bib63","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/08860220701460160","article-title":"Acute hepatitis C in patients receiving hemodialysis","volume":"29","author":"Griveas","year":"2007","journal-title":"Ren Fail"},{"key":"10.1016\/j.jhep.2008.07.005_bib64","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1046\/j.1365-2893.2001.00268.x","article-title":"Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment","volume":"8","author":"Gursoy","year":"2001","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2008.07.005_bib65","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1471-2458-7-50","article-title":"Acute hepatitis C virus infection assessment among chronic hemodialysis patients in the Southwest Parana State, Brazil","volume":"7","author":"Engel","year":"2007","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jhep.2008.07.005_bib66","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/hep.510380302","article-title":"The German network of excellence for viral hepatitis (Hep-Net)","volume":"38","author":"Manns","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2008.07.005_bib67","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jhep.2004.11.018","article-title":"Barriers to interferon-\u03b1 therapy are higher in intravenous drug users than in other patients with acute hepatitis C","volume":"42","author":"Broers","year":"2005","journal-title":"J Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827808004340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827808004340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T06:50:17Z","timestamp":1684479017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827808004340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S0168827808004340"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2008.07.005","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}